GlaxoSmithKline Pharmaceuticals Limited

rs,

G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read

8.6%

ion rate; VNM: Vitamins nutrients minerals; Vx: Vaccination 01 August 2025 3 Q1 FY26 IPM grew at 8.6%; GSK’s rep market grew at 6.6% due to slow growth in some of its key categories IPM growth is dri

6.6%

ts minerals; Vx: Vaccination 01 August 2025 3 Q1 FY26 IPM grew at 8.6%; GSK’s rep market grew at 6.6% due to slow growth in some of its key categories IPM growth is driven by price & new launches; a

7.2%

wth in some of its key categories IPM growth is driven by price & new launches; acute market grew 7.2% Key therapies for GSK - AI, Pain, and Derma - grew slower than IPM 8.6% Apr-Jun’25 IPM Gr. 4.6

4.6%

.2% Key therapies for GSK - AI, Pain, and Derma - grew slower than IPM 8.6% Apr-Jun’25 IPM Gr. 4.6% 1.6% 2.4% e c i r P l o V I N Chronic grew better by 3.5% vs acute increasing its industry

1.6%

ey therapies for GSK - AI, Pain, and Derma - grew slower than IPM 8.6% Apr-Jun’25 IPM Gr. 4.6% 1.6% 2.4% e c i r P l o V I N Chronic grew better by 3.5% vs acute increasing its industry contr

2.4%

erapies for GSK - AI, Pain, and Derma - grew slower than IPM 8.6% Apr-Jun’25 IPM Gr. 4.6% 1.6% 2.4% e c i r P l o V I N Chronic grew better by 3.5% vs acute increasing its industry contributi

3.5%

an IPM 8.6% Apr-Jun’25 IPM Gr. 4.6% 1.6% 2.4% e c i r P l o V I N Chronic grew better by 3.5% vs acute increasing its industry contribution Acute Chronic 60% 7.2% 40% 10.7% % Growth 13

60%

I N Chronic grew better by 3.5% vs acute increasing its industry contribution Acute Chronic 60% 7.2% 40% 10.7% % Growth 13.5 11.4 9.7 9.1 8.1 7.9 6.8 6.6 6.2 5.0 1.5 1.5 CARDIAC

40%

onic grew better by 3.5% vs acute increasing its industry contribution Acute Chronic 60% 7.2% 40% 10.7% % Growth 13.5 11.4 9.7 9.1 8.1 7.9 6.8 6.6 6.2 5.0 1.5 1.5 CARDIAC 12.5 GI

10.7%

grew better by 3.5% vs acute increasing its industry contribution Acute Chronic 60% 7.2% 40% 10.7% % Growth 13.5 11.4 9.7 9.1 8.1 7.9 6.8 6.6 6.2 5.0 1.5 1.5 CARDIAC 12.5 GI AI ANT

10.4 %

RESPI NEURO / CNS 6.9 5.8 8.6 7.9 6.9 6.0 12.2 10.2 GYNAE 5.2 HORMONES 7.7 VACCINES 10.4 % Contri Val Grwth % GSK’s rep market grew at 6.6% driven by the slower growth in few categories